Hematologic and Lymphocytic Disorder: Clinical Trials

7 trials for Hematologic and Lymphocytic Disorder, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 terminated, 2 active not recruiting, 1 completed, 1 withdrawn. 7 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 27Terminated 3, Active not recruiting 2, Completed 1, Withdrawn 1

Follow Hematologic and Lymphocytic Disorder: new trials by email Literature Review of Hematologic and Lymphocytic Disorder trials Research Report on Hematologic and Lymphocytic Disorder

Trials (filtered) newest first · largest first

All 7 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Itacitinib for the Prevention of Graft Versus Host Disease
Allogeneic Hematopoietic Stem Cell Transplantation, Busulfan, Cyclophosphamide - Hematologic and Lymphocytic Disorder
Phase 2Active not recruitingM.D. Anderson Cancer Center312022-01-112026-10-07
Ustekinumab for the Prevention of Acute Graft-versus-Host Disease After Unrelated Donor Hematopoietic Cell Transplant
Placebo Administration, Quality-of-Life Assessment, Questionnaire Administration - Hematologic and Lymphocytic Disorder, Hematopoietic and Lymphoid System Neoplasm
Phase 2Active not recruitingFred Hutchinson Cancer Center1162021-05-142026-01-02
Itacitinib, Tacrolimus, and Sirolimus for the Prevention of GVHD in Patients With Acute Leukemia, Myelodysplastic Syndrome, or Myelofibrosis Undergoing Reduced Intensity Conditioning Donor Stem Cell Transplantation
Fludarabine, Itacitinib Adipate, Melphalan - Acute Leukemia, Hematologic and Lymphocytic Disorder
Phase 2CompletedCity of Hope Medical Center592020-11-052026-11-03
Itacitinib for the Prevention of Graft Versus Host Disease in Patients Undergoing Donor Stem Cell Transplantation
Allogeneic Hematopoietic Stem Cell Transplantation, Busulfan, Fludarabine - Allogeneic Stem Cell Transplant Recipient, Hematologic and Lymphocytic Disorder
Phase 2WithdrawnM.D. Anderson Cancer Center2020-09-222020-10-29
AZA + Venetoclax as Maintenance Therapy in Patients With AML in Remission
Azacitidine, Venetoclax - Acute Myeloid Leukemia in Remission, FLT3 Gene Mutation
Phase 2TerminatedM.D. Anderson Cancer Center362019-09-132026-10-16
Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation
Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Cyclosporine - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Phase 2TerminatedFred Hutchinson Cancer Center1502017-09-112026-05-14
Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia
Platelet Transfusion - Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia
Phase 2TerminatedFred Hutchinson Cancer Center42017-06-092019-10-21

Narrower conditions

Hematologic Diseases (7)  ·  Leukemia, Myeloid, Acute (3)  ·  Myelodysplastic Syndromes (3)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (2)  ·  Leukemia, Myelogenous, Chronic, BCR-ABL Positive (2)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (2)  ·  Primary Myelofibrosis (2)  ·  Blastic Plasmacytoid Dendritic Cell Neoplasm (1)  ·  Hematologic Neoplasms (1)  ·  Hodgkin Disease (1)  ·  Leukemia, Biphenotypic, Acute (1)  ·  Leukemia, Prolymphocytic (1)  ·  Lymphoma, B-Cell (1)  ·  Lymphoma, Large B-Cell, Diffuse (1)  ·  Lymphoma, Mantle-Cell (1)

Broader conditions

Hemic and Lymphatic Diseases (7)  ·  Neoplasms (4)  ·  Bone Marrow Diseases (3)  ·  Leukemia (3)  ·  Leukemia, Myeloid (3)  ·  Myeloproliferative Disorders (3)  ·  Neoplasms by Histologic Type (3)  ·  Cardiovascular Diseases (2)  ·  Chronic Disease (2)  ·  Disease Attributes (2)  ·  Immune System Diseases (2)  ·  Immunoproliferative Disorders (2)  ·  Leukemia, B-Cell (2)  ·  Leukemia, Lymphoid (2)  ·  Lymphatic Diseases (2)

Interventions

Tacrolimus (3)  ·  fludarabine (3)  ·  Busulfan (2)  ·  Cyclophosphamide (2)  ·  INCB039110 (2)  ·  Sirolimus (2)  ·  itacitinib (2)  ·  Azacitidine (1)  ·  Cyclosporine (1)  ·  Cyclosporins (1)  ·  Disulfides (1)  ·  Immunoglobulin G (1)  ·  Interleukin-12 Subunit p40 (1)  ·  Melphalan (1)  ·  Methotrexate (1)

Sponsors

Fred Hutchinson Cancer Center (3)  ·  M.D. Anderson Cancer Center (3)  ·  City of Hope Medical Center (1)

Countries

United States (7)

Top investigators

David Garcia (1)  ·  Haris Ali (1)  ·  Masumi Ueda Oshima (1)  ·  Stephanie J. Lee (1)  ·  Tapan M Kadia (1)  ·  Uday R Popat (1)  ·  Uday R Popat, MD (1)

Results publications

PMID 38548404, PMID 41043099

NIH funding

P30CA015704 (2), P01CA078902 (1)